11：00 AM - 12：00 PM - Room La Nouvelle Orleans B
ABSORB - PW Serruys
Six-Month Angiographic and IVUS Results from This First-in-Man Evaluation of a Fully Bioabsorbable Everolimus-Eluting Coronary Stent --
Danish ST Trial - Michael Maeng
Stent Thrombosis After Implantation of Drug Eluting and Bare Metal Coronary Stents in Western Denmark --
COSTAR II - Mitchell W. Krucoff
Multicenter Randomized Evaluation of a Novel Paclitaxel Eluting Stent With Bioresorbable Polymer for the Treatment of Single and Multivessel Coronary Disease： Primary Results of the Cobalt Chromium Stent With Antiproliferative for Restenosis II Study
SPIRIT III - Gregg W. Stone
Clinical， Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease
Learning Objectives Describe the relative safety and efficacy profile of the everolimus-eluting Xience stent compared to the paclitaxel-eluting Taxus stent.
SPIRIT II - 12 months data
The SPIRIT II 12 month data will be presented as an ePoster by Dr Ruygrok. It is a new way to present in a more interactive way - Slides can be added to the poster presentation and people can post questions via the internet. No additional oral presentation will happen on this data at ACC：
Presentation Time： 2：00pm - 2：50pm
SPIRIT II Study： A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions.
Based on the acceptance of the ABSORB 6 month data we plan to submit 9 months data for PCR.